The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2, multicenter study to evaluate the efficacy and safety using autologous tumor infiltrating lymphocytes (LN-145) in patients with recurrent, metastatic, or persistent cervical carcinoma.
 
Amir A. Jazaeri
Honoraria - Genentech/Roche; Neon Therapeutics
Consulting or Advisory Role - Almac Group; Aravive; Genentech/Roche
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Lion Biotechnologies (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune
 
Robert P. Edwards
No Relationships to Disclose
 
Robert Michael Wenham
Stock and Other Ownership Interests - Ovation Sciences
Honoraria - Clovis Oncology; Tesaro
Consulting or Advisory Role - Clovis Oncology; Genentech; Ovation Sciences; Tesaro
Speakers' Bureau - Clovis Oncology; Genentech; Tesaro
Research Funding - Merck (Inst); Prescient Therapeutics (I); TapImmune Inc. (Inst)
 
KOJI MATSUO
No Relationships to Disclose
 
Gini F. Fleming
Research Funding - Corcept Therapeutics (Inst)
 
David M. O'Malley
Honoraria - Clovis Oncology
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Clovis Oncology; Janssen Oncology; Myriad Genetics; Novocure; Tesaro
Research Funding - Agenus (Inst); Ajinomoto (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Clovis Oncology (Inst); EMD Serono (Inst); Ergomed (Inst); Genentech/Roche (Inst); Immunogen (Inst); Immunogen (Inst); Janssen Research & Development (Inst); PharmaMar (Inst); Regeneron (Inst); Stem CentRx (Inst); Tesaro (Inst); TRACON Pharma (Inst); VentiRx (Inst)
 
Brian M. Slomovitz
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Tesaro
 
Bradley J. Monk
Leadership - US Oncology
Honoraria - Abbvie; Advaxis; Amgen; AstraZeneca; Bayer; Biodesix; Cerulean Pharma; Clovis Oncology; GlaxoSmithKline; Gradalis; Immunogen; Incyte; Insys Therapeutics; Janssen; Mateon Therapeutics; Merck; Myriad Pharmaceuticals; Nucana; Oxigene; Oxigene; Perthera; Pfizer; Precision Oncology; Roche/Genentech; Tesaro; Verastem; Vermillion
Consulting or Advisory Role - Abbvie; Advaxis; Amgen; AstraZeneca; Bayer; Biodesix; Cerulean Pharma; Clovis Oncology; GlaxoSmithKline; Gradalis; Immunogen; Incyte; Insys Therapeutics; Mateon Therapeutics; Merck; Myriad Pharmaceuticals; Nucana; Oxigene; Perthera; Pfizer; Precision Oncology; Roche/Genentech; Tesaro; Verastem; Vermillion
Speakers' Bureau - AstraZeneca; Clovis Oncology; Janssen; Roche/Genentech; Tesaro
Research Funding - Advaxis (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Genentech (Inst); Immunogen (Inst); Janssen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Nucana (Inst); Pfizer (Inst); Regeneron (Inst); Tesaro (Inst)
 
Robert James Brown
Employment - Insys Therapeutics; Iovance Biotherapeutics
Stock and Other Ownership Interests - Insys Therapeutics
 
Samuel Suzuki
Employment - Iovance Biotherapeutics
Stock and Other Ownership Interests - Iovance Biotherapeutics
 
Igor Gorbatchevsky
Employment - Bayer; Iovance Biotherapeutics
 
Maria Fardis
Employment - Acerta Pharma; Iovance Biotherapeutics
Leadership - Acerta Pharma; Iovance Biotherapeutics
Stock and Other Ownership Interests - Abbvie; Acerta Pharma; Gilead Sciences; Iovance Biotherapeutics
Patents, Royalties, Other Intellectual Property - Acerta Pharma (Inst); Iovance Biotherapeutics (Inst)
Travel, Accommodations, Expenses - Acerta Pharma; Iovance Biotherapeutics
 
Emese Zsiros
Consulting or Advisory Role - Iovance Biotherapeutics
Research Funding - Merck; X4 Pharma
Travel, Accommodations, Expenses - Iovance Biotherapeutics